Overcoming barriers to CAR-T therapy: improving access and cost

CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals with a high unmet medical need. Although CAR-T cells have demonstrated promising efficacy in patients, there are several challenges that need to be overcome before these are optimally used in clinical practice.  In this podcast, you will hear from Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, and Natacha Bolaños, Lymphoma Coalition Europe, Madrid, Spain, who discuss two major barriers to CAR-T therapy: the high cost of CAR-T cells and the need to improve access to these agents.